within Pharmacolibrary.Drugs.ATC.P;

model P03AA54
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.0016666666666666668,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0025,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P03AA54</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Disulfiram is a medication used to support the treatment of chronic alcoholism by producing an acute sensitivity to ethanol (alcohol). It is approved in several countries but is considered less commonly used today due to the availability of alternative treatments for alcohol dependence. Disulfiram is also applied in veterinary medicine and, in combination, for certain antiparasitic indications.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for typical adult individuals. No published studies report detailed population PK parameters for disulfiram, combinations (ATC P03AA54), so estimates are based on known values for disulfiram in adults.</p><h4>References</h4><ol><li><p>Wu, S, et al., &amp; Xia, J (2025). Disulfiram/Cu targeting FOXO6 modulates sensitivity of hepatocellular carcinoma to lenvatinib via disrupt choline metabolic. <i>Cellular signalling</i> 127 111563–None. DOI:<a href=\"https://doi.org/10.1016/j.cellsig.2024.111563\">10.1016/j.cellsig.2024.111563</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39694126/\">https://pubmed.ncbi.nlm.nih.gov/39694126</a></p></li><li><p>Saivin, S, et al., &amp; Houin, G (1998). Clinical pharmacokinetics of acamprosate. <i>Clinical pharmacokinetics</i> 35(5) 331–345. DOI:<a href=\"https://doi.org/10.2165/00003088-199835050-00001\">10.2165/00003088-199835050-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9839087/\">https://pubmed.ncbi.nlm.nih.gov/9839087</a></p></li><li><p>Fraser, AG (1997). Pharmacokinetic interactions between alcohol and other drugs. <i>Clinical pharmacokinetics</i> 33(2) 79–90. DOI:<a href=\"https://doi.org/10.2165/00003088-199733020-00001\">10.2165/00003088-199733020-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9260032/\">https://pubmed.ncbi.nlm.nih.gov/9260032</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P03AA54;
